Regenicin, Inc. is a biotechnology company, which specializes in the development of regenerative cell therapies to restore the health of damaged tissues and organs. It intends to develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures. The company was founded on September 6, 2007 and is headquartered in Little Falls, NJ.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company